September 16, 2015
Daiichi Sankyo said on September 15 that it has sealed an exclusive licensing accord with Translational Sciences Inc. to globally develop and commercialize the US biopharma’s thrombus dissolving agent TS23. The Memphis, Tennessee-based company is currently carrying out PI clinical...read more